The Pharmacoeconomics of Breakthrough Cancer Pain

REFERENCES

• Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain. 2009;13:331–338.
   PubMed Web of Science ®Google Scholar
• Haugen DF, Hjermstad MJ, Hagen N, Caraceni A, Kaasa S. Assessment and classification of cancer breakthrough pain: a systematic literature review. Pain. 2010;149:476–482.
   PubMed Web of Science ®Google Scholar
• Skinner C TE, Davies A. Cancer-Related Breakthrough Pain. Oxford, UK: Oxford University Press; 2006.
   Google Scholar
• Svendsen KB, Andersen S, Arnason S, Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain. 2005;9:195–206.
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain. 1990;41:273–281.
   PubMed Web of Science ®Google Scholar
• Coluzzi PH. Cancer pain management: newer perspectives on opioids and episodic pain. Am J Hosp Palliat Care. 1998;15:13–22.
   PubMedGoogle Scholar
• Hanks GW PR, MacDonald N, Forbes K. Oxford Textbook of Pallitative Medicine. New York: Oxford University Press; 1998.
   Google Scholar
• Zeppetella G, O'Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage. 2000;20:87–92.
   PubMed Web of Science ®Google Scholar
• Caraceni A, Portenoy RK. An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain. Pain. 1999;82:263–274.
   PubMed Web of Science ®Google Scholar
• Fortner BV, Demarco G, Irving G, Description and predictors of direct and indirect costs of pain reported by cancer patients. J Pain Symptom Manage. 2003;25:9–18.
   PubMed Web of Science ®Google Scholar
• Caraceni A, Martini C, Zecca E, Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med. 2004;18:177–183.
   PubMed Web of Science ®Google Scholar
• Webber K, Davies AN, Cowie MR. Breakthrough pain: a qualitative study involving patients with advanced cancer. Support Care Cancer. 2011;19:2041–2046.
   PubMed Web of Science ®Google Scholar
• Caraceni A, Hanks G, Kaasa S, Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13:e58–e68.
   PubMed Web of Science ®Google Scholar
• Ruiz-Garcia V, Lopez-Briz E. Morphine remains gold standard in breakthrough cancer pain. BMJ. 2008;337:a3104.
   Google Scholar
• McCarberg BH. The treatment of breakthrough pain. Pain Med. 2007;8(Suppl 1):S8–S13.
   PubMed Web of Science ®Google Scholar
• Center for the Evaluation of Value and Risk in Health. The Cost-Effectiveness Analysis Registry [Internet]. (Boston), Institute for Clinical Research and Health Policy Studies, Tufts Medical Center. Available from: HYPERLINK “http://www.cearegistry.org” www.cearegistry.org. Accessed on [2012.08.23].
   Google Scholar
• Llanes LR, Fassbender K, Baracos VE, Watanabe S. Drug utilization review on a tertiary palliative care unit. J Pain Symptom Manage. 2006;31:457–464.
   PubMed Web of Science ®Google Scholar
• Mercadante S, Porzio G, Ferrera P, Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. Eur J Pain. 2008;12:1040–1046.
   PubMed Web of Science ®Google Scholar
• Moulin DE, Kreeft JH, Murray-Parsons N, Bouquillon AI. Comparison of continuous subcutaneous and intravenous hydromorphone infusions for management of cancer pain. Lancet. 1991;337:465–468.
   PubMed Web of Science ®Google Scholar
• Grant M, Ferrell BR, Rivera LM, Lee J. Unscheduled readmissions for uncontrolled symptoms. A health care challenge for nurses. Nurs Clin North Am. 1995;30:673–682.
   PubMed Web of Science ®Google Scholar
• Fortner BV, Okon TA, Ashley J, The Zero Acceptance of Pain (ZAP)™ Quality Improvement Project: evaluation of pain severity, pain interference, global quality of life, and pain-related costs. J Pain Symptom Manage. 2003;25:334–343.
   PubMed Web of Science ®Google Scholar
• Fortner BV, Okon TA, Portenoy RK. A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. J Pain. 2002;3:38–44.
   PubMed Web of Science ®Google Scholar
• Vissers DC, Lenre M, Tolley K, Jakobsson J, Sendersky V, Jansen JP. An economic evaluation of short-acting opioids for treatment of breakthrough pain in patients with cancer. Value Health. 2011;14:274–281.
   PubMed Web of Science ®Google Scholar
• Abernethy AP, Samsa GP, Matchar DB. A clinical decision and economic analysis model of cancer pain management. Am J Manag Care. 2003;9:651–664.
   PubMed Web of Science ®Google Scholar
• Rascati KL. Essentials of Pharmacoeconomics. 1st ed. Philadelphia: Lippincott Williams & Wilkins; 2008.
   Google Scholar
• Doolittle GC, Harmon A, Williams A, A cost analysis of a tele-oncology practice. J Telemed Telecare. 1997;3(Suppl 1):20–22.
   PubMedGoogle Scholar
• Ferrell BR, Griffith H. Cost issues related to pain management: report from the Cancer Pain Panel of the Agency for Health Care Policy and Research. J Pain Symptom Manage. 1994;9:221–234.
   PubMed Web of Science ®Google Scholar
• Williams RM. Distribution of emergency department costs. Ann Emerg Med. 1996;28:671–676.
   PubMed Web of Science ®Google Scholar
• Gunnar B. Statistical Estimates and Transformed Beta-Variables. New York: John Wiley and Sons; 1958.
   Google Scholar
• Daut RL, Cleeland CS, Flanery RC. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain. 1983;17:197–210.
   PubMed Web of Science ®Google Scholar
• Jacox ACD, Payne R, Berde CB, Breitbart W, Cain JM, eds. Clinical Practice Guideline No. 9. Management of Cancer Pain. Rockville, MD: Agency for Health Care Policy and Research; 1994.
   Google Scholar
• Fisch MJ, Lee JW, Weiss M, Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. J Clin Oncol. 2012;30:1980–1988.
   PubMed Web of Science ®Google Scholar
• Abernethy AP, Wheeler JL, Fortner BV. A health economic model of breakthrough pain. Am J Manag Care. 2008;14(5 Suppl 1):S129–S140.
   PubMedGoogle Scholar
• Portenoy RK, Taylor D, Messina J, Tremmel L. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain. 2006;22:805–811.
   PubMed Web of Science ®Google Scholar
• Slatkin NE, Xie F, Messina J, Segal TJ. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol. 2007;5:327–334.
   PubMedGoogle Scholar
• Kress HG, Oronska A, Kaczmarek Z, Kaasa S, Colberg T, Nolte T. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period. Clin Ther. 2009;31:1177–1191.
   PubMed Web of Science ®Google Scholar
• Mercadante S, Radbruch L, Davies A, A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial. Curr Med Res Opin. 2009;25:2805–2815.
   PubMed Web of Science ®Google Scholar
• Farrar JT, Cleary J, Rauck R, Busch M, Nordbrock E. Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst. 1998;90:611–616.
   PubMed Web of Science ®Google Scholar
• Coluzzi PH, Schwartzberg L, Conroy JD, Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain. 2001;91:123–130.
   PubMed Web of Science ®Google Scholar
• Fallon M, Reale C, Davies A, Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study. J Support Oncol. 2011;9:224–231.
   PubMedGoogle Scholar